Search review questions

VAS scores for vertigo after 8 weeks of treatment · patients with Ménière's disease or syndrome

Loss or gain of hearing in 4 months (dB) · patients with Ménière's disease or syndrome

Cumulative activity score · patients with Ménière's disease or syndrome

Change in functional profile in the 8 weeks before and after 4 weeks of treatment · patients with Ménière's disease or syndrome

Sick days in 4 months · patients with Ménière's disease or syndrome

Psychomotor score Performance rating scale Scale from: 0 to 10 · surgical trainees

Procedural score Time to completion of task · surgical trainees

End‐product score Welling scale Scale from: 0 to 3.5 · surgical trainees

Procedural score Technical step binary scale · medical students

End‐product score Modified Welling scale · medical students

Anatomy score Anatomy identification test Scale from: 0 to 10 · medical students

Overall nasal symptom score 36 weeks post‐treatment · non‐allergic rhinitis

Daily record chart symptom resolution 4 weeks post‐treatment (capsaicin 4 μg/puff versus placebo) · non‐allergic rhinitis

Treatment‐related adverse events · non‐allergic rhinitis

Nasal obstruction during the 4th week of treatment Number of responders · patients with non‐allergic rhinitis

Aggregate relief score during the 4th week of treatment · patients with non‐allergic rhinitis

Treatment‐related adverse events · patients with non‐allergic rhinitis

Smell testing University of Pennsylvania Smell Identification Test (UPSIT) Scale from: 0 to 40 · patients with non‐allergic rhinitis

Treatment‐related adverse events · patients with non‐allergic rhinitis

Disease‐specific quality of life or symptoms [mean total scores at 7 months] · children with obstructive sleep‐disordered breathing

Adverse events, complications and morbidity associated with (adeno)tonsillectomy and comparators Expressed as the proportion of children experiencing adverse events [12 months] · children with obstructive sleep‐disordered breathing

Respiratory events during sleep as measured by the AHI using PSG [mean AHI at 12 months] · children with obstructive sleep‐disordered breathing

Adverse events, complications and morbidity associated with (adeno)tonsillectomy and comparators Expressed as the proportion of children experiencing a serious adverse event [7 months] · children with obstructive sleep‐disordered breathing

Respiratory events during sleep as measured by the AHI using PSG [mean AHI at 7 months] · children with obstructive sleep‐disordered breathing

Neurocognitive performance [7 months] · children with obstructive sleep‐disordered breathing

Attention [mean NEPSY at 7 months] · children with obstructive sleep‐disordered breathing

Behaviour [mean scores at 7 months] · children with obstructive sleep‐disordered breathing

Adverse events, complications and morbidity associated with (adeno)tonsillectomy and comparators [6 months] · children with obstructive sleep‐disordered breathing

Respiratory events during sleep as measured by the AHI using PSG [median AI at 6 months] · children with obstructive sleep‐disordered breathing

Disease‐specific quality of life or symptoms [mean score at 12 months] · children with obstructive sleep‐disordered breathing

Episodes of sore throat of any severity Including as 1 episode the period post‐surgery) · Children with chronic/recurrent acute tonsillitis

Episodes of moderate/severe sore throat(subgroup of severely affected patients) Including as 1 episode the period post‐surgery) · Children with chronic/recurrent acute tonsillitis

Episodes of moderate/severe sore throat(subgroup of moderately affected patients) Not including as 1 episode the period post‐surgery · Children with chronic/recurrent acute tonsillitis

Sore throat days (including those immediately post‐surgery · Children with chronic/recurrent acute tonsillitis

Absence from school or work (standardised to 180 school days or followed up for 5 to 6 months) · Children with chronic/recurrent acute tonsillitis

Complications ‐ results not pooled · Children with chronic/recurrent acute tonsillitis

All‐cause mortality ‐ not reported · Children with chronic/recurrent acute tonsillitis

Quality of life ‐ results not pooled · Children with chronic/recurrent acute tonsillitis

Patient‐reported disease‐specific symptom scores Symptom score with scale of 0 to 3 (0 = no symptoms, 3 = severe symptoms)

Health‐related quality of life scores, measured by SF‐36 (range 0 to 100)

Endoscopic appearances 0 to 3 (0 = no polyps, 3 = severe polyposis)

Complications

Objective physiological measures

Olfactory tests

Primary outcome: improvement in symptoms (respiratory distress/dyspnoea) · 23 patients aged two years or older with recurrent respiratory papillomatosis

Primary outcome: improvement in symptoms (voice quality) · 23 patients aged two years or older with recurrent respiratory papillomatosis

Primary outcome: improvement in quality of life · 23 patients aged two years or older with recurrent respiratory papillomatosis

Primary outcome: recurrence‐free interval · 23 patients aged two years or older with recurrent respiratory papillomatosis

Reduction in mortality · 23 patients aged two years or older with recurrent respiratory papillomatosis

Reduction in number and/or frequency of surgical interventions and/or time until first relapse requiring surgery · 23 patients aged two years or older with recurrent respiratory papillomatosis